Collegium Pharmaceutical, Inc.

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company focused on the development and commercialization of medicines for pain management. Its portfolio includes Jornay PM, a central nervous system stimulant prescription medicine containing methylphenidate HCl for treating attention deficit hyperactivity disorder (ADHD). Other products include Belbuca, a buccal film with buprenorphine for severe and persistent pain requiring extended treatment; Xtampza ER, an abuse-deterrent, extended-release oral formulation of oxycodone for pain severe enough to require daily management; Nucynta ER and Nucynta IR, extended-release and immediate-release oral formulations of tapentadol for acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for opioid-induced constipation in adult patients with chronic non-cancer pain.

Collegium Pharmaceutical, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol COLL. The company's stock is traded in U.S. dollars (USD), which is the official currency of the United States where the company is headquartered. As a Nasdaq-listed company, it operates within the U.S. equity market and reports its financial results in USD.

Collegium Pharmaceutical, Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. This classification means the company is involved in the development, production, and marketing of specialized pharmaceutical products, including both branded and generic medications. As a specialty pharmaceutical company, Collegium focuses on niche therapeutic areas, particularly pain management, and its products include abuse-deterrent formulations and other innovative drug delivery systems.

Collegium Pharmaceutical, Inc. is headquartered in Stoughton, Massachusetts, United States. The company was originally founded as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. It was incorporated in 2002. The company's primary operations are based in the U.S., and it focuses on the U.S. market for its pain management and ADHD treatments. Its headquarters location in Massachusetts places it within a major biotechnology and pharmaceutical hub on the East Coast.

Collegium Pharmaceutical's portfolio includes several key products for pain management and ADHD. Jornay PM is a central nervous system stimulant containing methylphenidate HCl for ADHD. Belbuca is a buccal film with buprenorphine for severe and persistent pain. Xtampza ER is an abuse-deterrent, extended-release oral oxycodone for daily pain management. Nucynta ER and Nucynta IR are tapentadol formulations for acute and persistent pain. Symproic is an oral naldemedine for opioid-induced constipation in chronic non-cancer pain patients. These products address various aspects of pain and related conditions, leveraging different drug delivery technologies.